175 related articles for article (PubMed ID: 28081601)
1. Combination Therapy of NSCLC Using Hsp90 Inhibitor and Doxorubicin Carrying Functional Nanoceria.
Sulthana S; Banerjee T; Kallu J; Vuppala SR; Heckert B; Naz S; Shelby T; Yambem O; Santra S
Mol Pharm; 2017 Mar; 14(3):875-884. PubMed ID: 28081601
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Efficacy of Lactonic Sophorolipids: Nanoceria-Assisted Combination Therapy of NSCLC using HDAC and Hsp90 Inhibitors.
Naz S; Banerjee T; Totsingan F; Woody K; Gross RA; Santra S
Nanotheranostics; 2021; 5(4):391-404. PubMed ID: 33912379
[No Abstract] [Full Text] [Related]
3. Nanomedicine-Assisted Combination Therapy of NSCLC: New Platinum-Based Anticancer Drug Synergizes the Therapeutic Efficacy of Ganetespib.
Kallu J; Banerjee T; Sulthana S; Darji S; Higginbotham R; Fletcher C; Gerasimchuk NN; Santra S
Nanotheranostics; 2019; 3(1):120-134. PubMed ID: 30899640
[No Abstract] [Full Text] [Related]
4. Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.
Wang Y; Liu H; Diao L; Potter A; Zhang J; Qiao Y; Wang J; Proia DA; Tailor R; Komaki R; Lin SH
Clin Cancer Res; 2016 Dec; 22(23):5876-5886. PubMed ID: 27354472
[TBL] [Abstract][Full Text] [Related]
5. Targeted Delivery and Redox Activity of Folic Acid-Functionalized Nanoceria in Tumor Cells.
Vassie JA; Whitelock JM; Lord MS
Mol Pharm; 2018 Mar; 15(3):994-1004. PubMed ID: 29397735
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab and CCR2 Inhibitor Nanoparticles Induce Cytotoxicity-Mediated Apoptosis in Doxorubicin-Treated Hepatic and Non-Small Lung Cancer Cells.
Abd-Rabou AA; Ahmed HH
Asian Pac J Cancer Prev; 2019 Jul; 20(7):2225-2238. PubMed ID: 31350989
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein 90 inhibitors in non-small-cell lung cancer.
Pillai RN; Ramalingam SS
Curr Opin Oncol; 2014 Mar; 26(2):159-64. PubMed ID: 24463348
[TBL] [Abstract][Full Text] [Related]
8. Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer.
Hijaz M; Das S; Mert I; Gupta A; Al-Wahab Z; Tebbe C; Dar S; Chhina J; Giri S; Munkarah A; Seal S; Rattan R
BMC Cancer; 2016 Mar; 16():220. PubMed ID: 26979107
[TBL] [Abstract][Full Text] [Related]
9. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
Lai CH; Park KS; Lee DH; Alberobello AT; Raffeld M; Pierobon M; Pin E; Petricoin Iii EF; Wang Y; Giaccone G
Oncogene; 2014 Oct; 33(40):4867-76. PubMed ID: 24166505
[TBL] [Abstract][Full Text] [Related]
10. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
Kurihara E; Shien K; Torigoe H; Takeda T; Takahashi Y; Ogoshi Y; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Okazaki M; Shien T; Tomida S; Toyooka S
Anticancer Res; 2019 Apr; 39(4):1767-1775. PubMed ID: 30952716
[TBL] [Abstract][Full Text] [Related]
11. HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy.
Lin TY; Guo W; Long Q; Ma A; Liu Q; Zhang H; Huang Y; Chandrasekaran S; Pan C; Lam KS; Li Y
Theranostics; 2016; 6(9):1324-35. PubMed ID: 27375782
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation.
Park SE; Kim DE; Kim MJ; Lee JS; Rho JK; Jeong SY; Choi EK; Kim CS; Hwang JJ
Oncol Rep; 2019 Jan; 41(1):525-533. PubMed ID: 30365122
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
Proia DA; Sang J; He S; Smith DL; Sequeira M; Zhang C; Liu Y; Ye S; Zhou D; Blackman RK; Foley KP; Koya K; Wada Y
Invest New Drugs; 2012 Dec; 30(6):2201-9. PubMed ID: 22227828
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
[TBL] [Abstract][Full Text] [Related]
16. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
[TBL] [Abstract][Full Text] [Related]
17. HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer.
O'Connell BC; O'Callaghan K; Tillotson B; Douglas M; Hafeez N; West KA; Stern H; Ali JA; Changelian P; Fritz CC; Palombella VJ; McGovern K; Kutok JL
PLoS One; 2014; 9(12):e115228. PubMed ID: 25542032
[TBL] [Abstract][Full Text] [Related]
18. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
Hong SW; Park NS; Noh MH; Shim JA; Ahn BN; Kim YS; Kim D; Lee HK; Hur DY
Lung Cancer; 2017 Apr; 106():115-124. PubMed ID: 28285685
[TBL] [Abstract][Full Text] [Related]
20. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition.
Jiang Y; Yang N; Zhang H; Sun B; Hou C; Ji C; Zheng J; Liu Y; Zuo P
J Control Release; 2016 Jan; 221():26-36. PubMed ID: 26643616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
